Summary & Overview
HCPCS J2502: Pasireotide Long-Acting Injection, 1 mg
HCPCS Level II code J2502 designates a long‑acting injectable formulation of pasireotide (1 mg). As a drug‑specific J‑code, it identifies the administered medication for billing and reporting across outpatient and infusion settings. Precise coding for long‑acting agents like pasireotide matters nationally because it ties directly to drug reimbursement, prior authorization workflows, and facility billing in ambulatory and hospital outpatient environments.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and the types of administrative considerations associated with J‑codes for specialty injectables. The publication summarizes common billing modifiers encountered with specialty drug J‑codes, discusses payer coverage patterns and authorization practices at a national level, and highlights benchmarking areas such as claim adjudication and site‑of‑service reporting.
This resource is intended for coding professionals, revenue cycle staff, and clinical administrators seeking a focused reference on HCPCS Level II code J2502 — what it represents, where it is used, and the operational topics to monitor when billing for long‑acting injectable pasireotide.
Billing Code Overview
HCPCS Level II code J2502 represents injection, pasireotide long acting, 1 mg. This billing code describes a long‑acting injectable formulation of pasireotide, a somatostatin analogue used in clinical settings that require extended‑release medication delivery.
Service type: Long‑acting injectable medication administration
Typical site of service: Outpatient clinic, ambulatory infusion center, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with Cushing disease or acromegaly who requires long‑acting somatostatin analogue therapy. The patient has been evaluated by an endocrinologist in an outpatient specialty clinic and meets criteria for treatment with pasireotide long‑acting injection. On the day of service the patient arrives for a scheduled intramuscular injection administered by a registered nurse in the clinic or ambulatory infusion center. The clinical workflow includes verification of the medication order for J2502 (pasireotide long acting, 1 mg), review of allergies and baseline vital signs, documentation of consent and indication, preparation of the long‑acting formulation per manufacturer instructions, administration via deep intramuscular injection (typically gluteal), observation for immediate adverse reactions for 30 minutes, and documentation of lot number and units administered in the medical record. Billing is submitted using the HCPCS level II code J2502 with applicable modifiers to indicate circumstances such as administration location, syringe/partial vial discard, or professional/provider relationship. Typical sites of service are outpatient physician office, ambulatory infusion center, or hospital outpatient department for patients requiring monitored administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |